Drug intelligence / Profile preview

SkinPlus-HYAL

Development stage: Unknown
Lead developer: Bioplus
Administration: Intradermal

Overview

SkinPlus-HYAL is a crosslinked hyaluronic acid-based dermal filler developed by BioPlus. It is designed for the temporary correction of moderate to severe facial wrinkles and folds, specifically nasolabial folds. The product utilizes a patented crosslinking technology to enhance the longevity and stability of the hyaluronic acid gel within the tissue. Some formulations, such as SkinPlus-HYAL Implant Lidocaine, include lidocaine to minimize pain during the injection procedure. Clinical trials have demonstrated that SkinPlus-HYAL is non-inferior to established fillers like Restylane in terms of efficacy, safety, and patient satisfaction for facial aesthetic augmentation.

Brand names: SkinPlus-HYALSkinPlus-HYAL Implant Lidocaine
Other names: SkinPlus-Hyal

Beyond the preview

Go deeper on SkinPlus-HYAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SkinPlus-HYAL.

Explore the full profile